Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Imuran Clear all
Completed Phase 2 Interventional

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

NCT02598596
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Azathioprine
Biological · Drug
Lead sponsor
Ampel BioSolutions, LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Huntsville, Alabama • Wheaton, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 2 Interventional Results available

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

NCT05263505
View directory record Official record
Conditions
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
Interventions
Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

NCT00262405
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
zileuton, azathioprine/prednisone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 5, 2026, 2:39 AM EDT
Active, not recruiting Phase 4 Interventional

Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

NCT05060991
View directory record Official record
Conditions
COVID-19, Immunosuppression, Vaccine Response Impaired
Interventions
Reduction in antimetabolite immunosuppression
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

NCT03760003
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
San Diego, California • Decatur, Georgia • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00531817
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Permitted DMARDs
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
156
States / cities
Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

NCT00650091
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 5, 2026, 2:39 AM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional Results available

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Edecesertib, Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression

NCT01733056
View directory record Official record
Conditions
Immunosuppression
Interventions
Flu Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

NCT02028884
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo, Baseline Treatment
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 74 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 5, 2026, 2:39 AM EDT
Recruiting Early Phase 1 Interventional

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

NCT04469842
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Not listed Early Phase 1 Interventional

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

NCT04726553
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Anifrolumab, Standard of Care
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 5, 2026, 2:39 AM EDT
Completed No phase listed Observational Results available

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539
View directory record Official record
Conditions
Neurological Disorder, Autoimmune Diseases
Interventions
Mycophenolate Mofetil, Azathioprine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Palo Alto, California • Miami, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 4 Interventional Results available

Once Daily Immunosuppression Regimen

NCT03555448
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
Once daily immunosuppression regimen, Twice daily immunosuppression regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 5, 2026, 2:39 AM EDT
Active, not recruiting Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

NCT02994927
View directory record Official record
Conditions
ANCA-Associated Vasculitis
Interventions
Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
41
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 5, 2026, 2:39 AM EDT
Not listed Phase 3 Interventional

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Azathioprine
Biological · Drug
Lead sponsor
Gastroenterology Research of America
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)

NCT00987831
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Group B SLE one blood donation, Blood drawing only Group C, Group A SLE prospective study
Other · Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
14 Years to 70 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Collegeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 5, 2026, 2:39 AM EDT
Not listed No phase listed Observational

Systemic Therapies for Pediatric Atopic Dermatitis

NCT01447381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2012 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 5, 2026, 2:39 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Uterus Transplantation to Treat Infertility

NCT05646992
View directory record Official record
Conditions
Uterine Factor Infertility
Interventions
Uterine Allotransplantation, Tacrolimus, Imuran
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2043
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 5, 2026, 2:39 AM EDT
Terminated Phase 4 Interventional

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

NCT04773392
View directory record Official record
Conditions
Kidney Transplantation, Kidney Transplant Rejection
Interventions
Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG), Methylprednisolone, prednisone, Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA), Azathioprine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 5, 2026, 2:39 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 5, 2026, 2:39 AM EDT